About two months ago, just after the Johnson & Johnson Covid-19 vaccine was cleared for emergency use by the FDA, we turned to Dr. Richard Firshein for a side-by-side breakdown and comparison of the three vaccines currently available in the US, including Moderna and Pfizer (read here). Dr. Firshein is one of the leading authorities and practitioners of integrative medicine, and our go-to expert for the most cutting-edge medical news and information.
At that time, there were high hopes for the Johnson & Johnson vaccine. It required just one dose and could be stored at temperatures similar to any other vaccine. Unlike Pfizer and Moderna, which require two doses and subzero refrigeration, the Johnson & Johnson vaccine would be far easier to distribute and get into people’s arms… the primary goal of all three.
Fast forward six weeks to April 13th when both the U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) recommended a pause in the Johnson & Johnson vaccinations after rare blood clotting occurred in six recipients causing serious illnesses, and in one case death. All six were women between the ages of 18 and 48, and all developed the illnesses within one to three weeks of vaccination.
10 days later following a thorough safety review, the FDA and CDC recommended resuming the Johnson & Johnson vaccinations, citing that the vaccine’s benefits outweighed its known and potential risks in individuals 18 years and older. Out of the roughly 7 million people in the United States who had received Johnson & Johnson shots at that time, the chance of these serious and life-threatening side effects was about one in a million. Read More